Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Sponsor: Hansoh BioMedical R&D Company
Summary
The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.
Official title: A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors Who Have Failed Adequate Standard Treatments or Are Intolerant to Standard Therapies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2025-09-23
Completion Date
2026-08-31
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Interventions
HS-20093
All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days.
Itraconazole
Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21
Locations (1)
Hunan Cancer Hospital
Changsha, Hunan, China